Clinical Trial Update: Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Sintilimab+Bevacizumab+TACE versus Lenvatinib+TACE for advanced hepatocellular carcinoma non-resectable; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Lenvatinib (lenvatinib)
• Sintilimab (sintilimab)
• TACE

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 3 | Status: RECRUITING